Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters